SLAM Bio is pioneering innovative cancer therapies, developing first-in-class human monoclonal antibodies, bispecifics and ADCs designed to target a family of proteins with high expression in a broad spectrum of blood cancers. The company's therapeutic platform has the potential to transform cancer treatment and significantly improve the lives of patients with life-threatening conditions like AML, MDS, CTCL and FL.